Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 5, 2013, Pages 848-854

  Alexander, Jacob ^a   Torbenson, Michael ^b   Wu, Tsung Teh ^c   Yeh, Matthew M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Non alcoholic fatty liver disease; Non cirrhotic hepatic steatosis; Risk factor

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 84876951873     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12116     Document Type: Article

References (47)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 2009; 27: 1485-1491.
4. Regimbeau JM, Colombat M, Mognol P etal. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004; 10: S69-73.
5. Donadon V, Balbi M, Ghersetti M etal. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol. 2009; 15: 2506-2511.
6. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539.
7. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am. J. Gastroenterol. 2001; 96: 2462-2467.
8. Polesel J, Zucchetto A, Montella M etal. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol. 2009; 20: 353-357.
9. Gao C, Yao SK. Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat. Dis. Int. 2009; 8: 465-473.
10. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 2006; 4: 369-380.
11. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am. J. Gastroenterol. 2012; 107: 46-52.
12. Adami HO, Chow WH, Nyren O etal. Excess risk of primary liver cancer in patients with diabetes mellitus. J. Natl Cancer Inst. 1996; 88: 1472-1477.
13. Verbaan H, Hoffmann G, Lindgren S, Nilsson S, Widell A, Eriksson S. Long-term outcome of chronic hepatitis C infection in a low-prevalence area. Scand. J. Gastroenterol. 1998; 33: 650-655.
14. Lawson DH, Gray JM, McKillop C, Clarke J, Lee FD, Patrick RS. Diabetes mellitus and primary hepatocellular carcinoma. Q. J. Med. 1986; 61: 945-955.
15. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
16. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 2012; 10: 1342-1592.
17. Bhala N, Angulo P, van der Poorten D etal. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216.
18. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 2009; 24: 248-254.
19. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
20. Tanaka A, Uegaki S, Kurihara H etal. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J. Gastroenterol. 2007; 13: 5180-5187.
21. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-2496.
22. Ohata K, Hamasaki K, Toriyama K etal. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-3043.
23. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011; 34: 274-285.
24. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005; 129: 375-378.
25. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
26. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-471.
27. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
28. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am. J. Surg. Pathol. 2010; 34: 1630-1636.
29. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-2474.
30. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010; 28: 155-161.
31. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006; 40 (Suppl. 1): S5-10.
32. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin. Liver Dis. 2012; 32: 30-38.
33. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 2002; 35: S72-78.
34. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 2007; 11: 191-207, x-xi.
35. Williams CD, Stengel J, Asike MI etal. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
36. Ertle J, Dechene A, Sowa JP etal. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 2011; 128: 2436-2443.
37. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J. Gastroenterol. 2010; 16: 1436-1441.
38. Paradis V, Zalinski S, Chelbi E etal. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
39. Hashimoto E, Yatsuji S, Tobari M etal. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 2009; 44 (Suppl. 19): 89-95.
40. Chagas AL, Kikuchi LO, Oliveira CP etal. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz. J. Med. Biol. Res. 2009; 42: 958-962.
41. Hashizume H, Sato K, Takagi H etal. Primary liver cancers with nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 2007; 19: 827-834.
42. Shimada M, Hashimoto E, Taniai M etal. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37: 154-160.
43. Rahman RN, Ibdah JA. Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: A population based study. The Liver Meeting® 2012: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA 2012.
44. Chao LT, Wu CF, Sung FY etal. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 2011; 32: 876-881.
45. Calvisi DF, Ladu S, Hironaka K, Factor VM, Thorgeirsson SS, Vitamin E. down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer. J. Hepatol. 2004; 41: 815-822.
46. Galicia VA, He L, Dang H etal. Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology 2010; 139: 2170-2182.
47. Hsu SH, Wang B, Kota J etal. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122. J. Clin. Invest. 2012; 122: 2871-2883.